Tags: Coronavirus | covid | virus | testmakers | pfizer | vaccine

Virus Testmakers Dealt $38 Billion Blow by Pfizer's Vaccine

Virus Testmakers Dealt $38 Billion Blow by Pfizer's Vaccine
(Monika Wisniewska/Dreamstime)

Monday, 09 November 2020 04:23 PM

Promising results from a study of Pfizer Inc. and BioNTech SE’s vaccine for Covid-19 sent companies that have developed and sold tests to diagnose the condition spiraling, wiping out more than $47 billion in market value across more than a dozen stocks.

Concerns about the sustainability of profits for the testing-kit market erased more than a quarter of Quidel Corp.’s value. High-flying stocks including Hologic Inc. and Qiagen tumbled 7.8% or more, while competitors like Thermo Fisher Scientific Inc., Abbott Laboratories, and Danaher Corp. shed billions in value as their stocks tumbled.

Some industry watchers had been optimistic for the group’s resilience despite advancements for vaccines and therapies to combat the coronavirus. Investors and analysts had argued that even with the development and rollout of a successful shot -- or shots -- there would still be demand for tests into 2022.

© Copyright 2021 Bloomberg News. All rights reserved.


   
1Like our page
2Share
StreetTalk
Promising results from a study of Pfizer Inc. and BioNTech SE's vaccine for Covid-19 sent companies that have developed and sold tests to diagnose the condition spiraling, wiping out about $38 billion in market value across more than a dozen stocks.Concerns about the...
covid, virus, testmakers, pfizer, vaccine
141
2020-23-09
Monday, 09 November 2020 04:23 PM
Newsmax Media, Inc.
 
Newsmax TV Live

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved